SKELETAL CELL THERAPY SUPPORT
abbreviatedSCTSInactiveInactive; last annual accounts for fiscal year 2021.
Signals
1 signal. The signal on the left, the evidence on the right.
○neutral
neutral · Latest accounts filed on time
The financial year that closed on 30-06-2021 was due by 31-01-2022 and was filed on 19-01-2022, 12 days ahead of the deadline.
NBB · 9 filingsDeviation from the deadline
2021
12 d early
2019
46 d early
2018
40 d early
2017
43 d early
2016
55 d early
2015
32 d early
2014
32 d early
← before the deadline
after the deadline →
Checked, nothing found (1)
Financials · fiscal year 2021, full schema
Turnover
€464k
EBIT margin
-315.1%
Net result
€-1.37M
Working capital
€-534k
Balance-sheet composition
Assets €7.35M
Fixed assets
€6.92M
Current assets
€430k
Equity and liabilities €7.35M
Equity
€6.34M
Debt
€1.02M
Debt finances 13.8% of the balance-sheet total.
Key figures and ratios
EBITDA
€-626k
Cash flow
€-538k
Current ratio
0.45
Debt to equity
0.01
ROE
-21.7%
ROA
-18.7%
Interest coverage
-6.31
Debt ≤ 1 year
€964k
Debt > 1 year
€54k
Income taxes
€-19k
Filed annual accounts As filed with the NBB · 2021 · 27 lines
Balance sheet
Code2021
Assets
Total assets20/58€7.35M
Fixed assets21/28€6.92M
Tangible fixed assets22/27€6.64M
Financial fixed assets28€281k
Current assets29/58€430k
Amounts receivable within one year40/41€136k
Current investments50/53€55k
Cash at bank and in hand54/58€215k
Equity and liabilities
Total equity and liabilities10/49€7.35M
Equity10/15€6.34M
Contributions10/11€5.58M
Reserves13€19k
Profit (loss) carried forward14€-1.09M
Amounts payable17/49€1.02M
Amounts payable after more than one year17€54k
Amounts payable within one year42/48€964k
Trade debts44€811k
Income statement
Code2021
Turnover70€464k
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€837k
Operating profit (loss)9901€-1.46M
Recurring financial income75€190k
Recurring financial charges65€121k
Debt charges650€99k
Profit (loss) for the period before taxes9903€-1.39M
Income taxes67/77€-19k
Profit (loss) for the period9904€-1.37M
Profit (loss) for the period to be appropriated9905€-1.37M
Accounts by statement
| Line | 2021 |
|---|---|
| Turnover70 | €464k |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €837k |
| Operating profit (loss)9901 | €-1.46M |
| Recurring financial income75 | €190k |
| Recurring financial charges65 | €121k |
| Debt charges650 | €99k |
| Profit (loss) for the period before taxes9903 | €-1.39M |
| Income taxes67/77 | €-19k |
| Profit (loss) for the period9904 | €-1.37M |
| Profit (loss) for the period to be appropriated9905 | €-1.37M |
| Line | 2021 | |
|---|---|---|
| Assets | ||
| Total assets20/58 | €7.35M | |
| Fixed assets21/28 | €6.92M | |
| Tangible fixed assets22/27 | €6.64M | |
| Financial fixed assets28 | €281k | |
| Current assets29/58 | €430k | |
| Amounts receivable within one year40/41 | €136k | |
| Current investments50/53 | €55k | |
| Cash at bank and in hand54/58 | €215k | |
| Equity and liabilities | ||
| Total equity and liabilities10/49 | €7.35M | |
| Equity10/15 | €6.34M | |
| Contributions10/11 | €5.58M | |
| Reserves13 | €19k | |
| Profit (loss) carried forward14 | €-1.09M | |
| Amounts payable17/49 | €1.02M | |
| Amounts payable after more than one year17 | €54k | |
| Amounts payable within one year42/48 | €964k | |
| Trade debts44 | €811k | |
| Line | 2021 |
|---|---|
| Profit (loss) for the period9904 | €-1.37M |
| + Depreciation and write-downs630 | €837k |
| Operating cash flow (approximation) | €-538k |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2022
19-01
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
2021
09-11
State Gazette act
Merger · Accounting effect
Power of attorney
2020
15-06
NBB filing
Annual accounts filed
fiscal year 2019 · full schema
2019
21-06
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
2018
18-06
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2017
06-06
NBB filing
Annual accounts filed
fiscal year 2016 · full schema
2016
29-06
NBB filing
Annual accounts filed
fiscal year 2015 · full schema
2015
29-06
NBB filing
Annual accounts filed
fiscal year 2014 · full schema
2014
27-06
NBB filing
Annual accounts filed
fiscal year 2013 · full schema
2013
26-06
NBB filing
Annual accounts filed
fiscal year 2012 · full schema
State Gazette actNBB filing
0 of 19 acts read
About the unread acts
We know of 19 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Structure & network
Ownership & control
1 parent companyControl over this companyparent company per the LEI register1
Tubize
controls
SKELETAL CELL THERAPY SUPPORT, EN ABREGE : SCTSBE 0841.570.812
Acquisitions and mergers
1 transactionTaken over by:Catalent Gosselies SA
Recognitions · licences · registrations
Legal Entity Identifier
549300AMMNSV1RPRXX43